4000-520-616
欢迎来到免疫在线!(蚂蚁淘生物旗下平台)  请登录 |  免费注册 |  询价篮
主营:原厂直采,平行进口,授权代理(蚂蚁淘为您服务)
咨询热线电话
4000-520-616
当前位置: 首页 > 产品中心 > peptide > Immunoway/Alpelisib(BYL-719)/10mg 50mg 100mg/MC0318
商品详细Immunoway/Alpelisib(BYL-719)/10mg 50mg 100mg/MC0318
Immunoway/Alpelisib(BYL-719)/10mg 50mg 100mg/MC0318
Immunoway/Alpelisib(BYL-719)/10mg 50mg 100mg/MC0318
商品编号: MC0318
品牌: Immunoway
市场价: ¥3600.00
美元价: 1800.00
产地: 美国(厂家直采)
公司:
产品分类: 多肽合成
公司分类: peptide
联系Q Q: 3392242852
电话号码: 4000-520-616
电子邮箱: info@ebiomall.com
商品介绍

    Alpelisib(BYL-719)

    • Catalog No.:MC0318
    • Data Sheet
    • MSDS
    • Support
    • Description
    • References ( 0 )
    • Protocol
      • CasNo:
      • 1217486-61-7
      • MolecularFormula:
      • C19H22F3N5O2S
      • Purity:
      • >98%
      • Target:
      • PI3K
      • IC50:
      • IC50: 5 nM (p110α), 250 (p110γ), 290 (p110δ), 1200 (p110β)[1]
      • In Vitro:
      • BYL-719 (NVP-BYL719) potently inhibits the 2 most common PIK3CA somatic mutations (H1047R, E545K; IC50∼4 nM). BYL-719 potently inhibits Akt phosphorylation in cells transformed with PI3Kα (IC50=74±15 nM) and shows significant reduced inhibitory activity in PI3Kβ or PI3Kδ isoforms transformed cells (≥15-fold compared with PI3Kα)[2]. BYL-719 (BYL719) decreases cell proliferation by blocking cell cycle in G0/G1 phase with no outstanding effects on apoptosis cell death in HOS and MOS-J tumor cells. BYL-719 inhibits cell migration and can thus be considered as a cytostatic drug for osteosarcoma. In murine preclinical models of osteosarcoma, BYL-719 significantly decreases tumor progression and tumor ectopic bone formation as shown by a decrease of Ki67+ cells and tumor vascularization. BYL-719 rapidly inhibits the levels of P-AKT and P-mTOR in all cell lines assessed, confirming the functional activity of BYL-719 on osteosarcoma cells. After 72 hr of treatment, BYL-719 significantly inhibit
      • In Vivo:
      • BYL-719 displays excellent oral bioavailability in rats, mice and dogs and does not show any significant inhibition of the CYP450 enzymes[1]. BYL-719 (BYL719) inhibits tumor growth in pre-clinical murine models of osteosarcoma. C57Bl/6J with MOS-J tumors (n=6 per group) are randomized as controls (vehicle) or BYL-719 (12.5 mg/kg or 50 mg/kg per day)[3].
      • Fields:
      • BYL719 is a potent and selective PI3Kα inhibitor with IC50 of 5 nM, ;liitle or no effect on PI3Kβ/γ/δ.
      • Specificity:
      • Target:PI3K. Fields: BYL719 is a potent and selective PI3Kα inhibitor with IC50 of 5 nM, ;liitle or no effect on PI3Kβ/γ/δ.
      • Source:
      • Rabbit
      • Dilution:
      • IC50: 5 nM (p110α), 250 (p110γ), 290 (p110δ), 1200 (p110β)[1]
      • Concentration:
      • >98%
      • Storage Stability:
      • 2 years -20°C Powder, 2 weeks4°C in DMSO,6 months-80°C in DMSO
      • Other Name:
      • BYL 719; BYL719
      • MolecularWeight(Da):
      • 441.47
      • References:
      • [1]. Furet P, et al. Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation. Bioorg Med Chem Lett. 2013 Jul 1;23(13):3741-8.[2].
      • June 19-2018
      • WESTERN IMMUNOBLOTTING PROTOCOL
      • June 19-2018
      • IMMUNOHISTOCHEMISTRY-PARAFFIN PROTOCOL
      • June 19-2018
      • IMMUNOFLUORESCENCE PROTOCOL
      • September 08-2020
      • FLOW-CYTOMEYRT-PROTOCOL
      • July 13-2018
      • CELL-BASED-ELISA-PROTOCOL-FOR-ACETYL-PROTEIN
      • July 13-2018
      • CELL-BASED-ELISA-PROTOCOL-FOR-PHOSPHO-PROTEIN
      • July 13-2018
      • CELL-BASED-COLORIMETRIC-ELISA-PROTOCOL-FOR-TOTAL-PROTEIN
      • July 13-2018
      • Antibody-FAQs
      • Products Images
      品牌介绍
      ImmunowayImmunoWay Biotechnology,我们的使命是帮助世界各地的生命科学研究人员通过更好的产品和服务简化和加速他们的研究。我们专注于开发用于免疫学和细胞学检测的创新和可靠的产品。我们一直是开发高质量ELISA试剂盒,代谢检测试剂盒,抗体和抗体/蛋白质微阵列的先驱,参与癌症,细胞凋亡,细胞生长和信号转导。ImmunoWay Biotechnology,我们的使命是通过更好的产品和服务帮助世界各地的生命科学研究者简化和加速他们的研究。我们专注于开发创新和可靠的产品,用于免疫学和细胞学检测。我们一直是开发涉及癌症,细胞凋亡,细胞生长和信号转导的高质量ELISA试剂盒,代谢测定试剂盒,抗体和抗体/蛋白质微阵列的先驱。